▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #426 by analyst upside · 2026-08-14
ENTX
Entera Bio Ltd.
Healthcare · Market Cap $141M · P/E 0x
ANALYST PRICE TARGET
+213.6%
implied upside to consensus target
Current Price $2.87
Consensus Target $9.0
Bull Target $9.0
Bear Target $9.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $0.91
52-Week High $4.2
YTD Return +62.1%
FUNDAMENTALS
Market Cap $141M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.35
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.91
52-Week High $4.2
Current Price $2.87
Bear Target $9.0
Bull Target $9.0
● Now $2.87 ● Target $9.0
TRADING DATA
Avg Volume 2.6M
YTD Return +62.1%
Analyst Count 1
Consensus Buy
Upside to Target +213.6%
Last Updated 2026-08-14

ANALYST SUMMARY

Entera Bio Ltd. (ENTX) is currently trading at $2.87 with a Wall Street consensus price target of $9.0, implying potential upside of 213.6% over the next 12 months. 1 analysts currently cover ENTX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $9.0.

ENTX operates in the Healthcare sector with a market capitalisation of $141M. The stock is up 62.1% year-to-date and is currently trading near the upper end of its 52-week range of $0.91 – $4.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

FBIO +269.1%
Fortress Biotech, Inc.
$99M · P/E 0.9x · Buy
SPRO +222.6%
Spero Therapeutics, Inc.
$72M · P/E 4.4x · Hold
CCLD +150.0%
CareCloud, Inc.
$104M · P/E 35.0x · Buy
AGEN +178.6%
Agenus Inc.
$315M · P/E 2.3x · Buy
SABS +210.3%
SAB Biotherapeutics, Inc.
$341M · P/E 15.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ENTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-27 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-09 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-18 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-11-11 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-10-07 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-09-27 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-08-12 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →